<article title='Antianginal'><paragraph>An<space/><bold>antianginal</bold><space/>is any<space/><link><target>Medication</target><part>drug</part></link><space/>used in the treatment of<space/><italics><link><target>angina pectoris</target></link></italics>, a symptom of<space/><link><target>coronary heart disease</target><part>ischaemic heart disease</part></link>.</paragraph><heading level='2'>Types</heading><heading level='3'>Stable Angina</heading><paragraph>Pain due to atherosclerosis causing incomplete coronary artery occlusion. Pain onset with strenuous activity or emotional strain due to increased myocardial oxygen demand.</paragraph><heading level='3'>Unstable Angina</heading><paragraph>Pain due to atherosclerotic plaque rupture and subsequent embolization causing incomplete coronary arterial occlusion.</paragraph><heading level='3'>Variant (Prinzmetal's) Angina</heading><paragraph>Pain due to transient vasospasm causing coronary artery vasoconstriction.</paragraph><heading level='2'>Examples</heading><paragraph>Drugs used are<space/><link><target>nitrate</target><trail>s</trail></link>,<space/><link><target>beta blocker</target><trail>s</trail></link>, or<space/><link><target>calcium channel blocker</target><trail>s</trail></link>.</paragraph><heading level='3'>Nitrates</heading><paragraph><template><target>Main</target><arg>Nitrovasodilator</arg></template><link><target>Nitrate</target><trail>s</trail></link><space/>cause<space/><link><target>vasodilation</target></link><extension extension_name='ref' name="pmid9875113"><template><target>cite journal</target><arg name="author">Pfister M, Seiler C, Fleisch M, Göbel H, Lüscher T, Meier B<space/></arg><arg name="title">Nitrate induced coronary vasodilatation: differential effects of sublingual application by capsule or spray<space/></arg><arg name="journal">Heart<space/></arg><arg name="volume">80<space/></arg><arg name="issue">4<space/></arg><arg name="pages">365–9<space/></arg><arg name="date">October 1998<space/></arg><arg name="pmid">9875113<space/></arg><arg name="pmc">1728824<space/></arg><arg name="doi"><space/>10.1136/hrt.80.4.365<space/></arg><arg name="url">http://heart.bmj.com/cgi/pmidlookup?view</arg></template></extension><space/>of the venous capacitance vessels by stimulating the<space/><link><target>endothelium-derived relaxing factor</target></link><space/>(EDRF). Used to relieve both exertional and vasospastic angina by allowing venous pooling, reducing the pressure in the ventricles and so reducing wall tension and oxygen requirements in the heart. Short-acting nitrates are used to abort angina attacks that have occurred, while longer-acting nitrates are used in the prophylactic management of the condition.</paragraph><paragraph>Agents include<space/><link><target>nitroglycerin</target></link><space/>(<link><target>glyceryl trinitrate</target></link>) or<space/><link><target>pentaerythritol tetranitrate</target></link>,<space/><link><target>isosorbide dinitrate</target></link><space/>and<space/><link><target>isosorbide mononitrate</target></link>.</paragraph><heading level='3'>Beta blockers</heading><paragraph><link><target>Beta blocker</target><trail>s</trail></link><space/>are used in the prophylaxis<extension extension_name='ref' name="pmid17998992"><template><target>cite journal</target><arg name="author">O'Rourke ST<space/></arg><arg name="title">Antianginal actions of beta-adrenoceptor antagonists<space/></arg><arg name="journal">Am J Pharm Educ<space/></arg><arg name="volume">71<space/></arg><arg name="issue">5<space/></arg><arg name="pages">95<space/></arg><arg name="date">October 2007<space/></arg><arg name="pmid">17998992<space/></arg><arg name="pmc">2064893<space/></arg><arg name="doi"><space/>10.5688/aj710595</arg><arg name="url"></arg></template></extension><space/>of exertional angina by reducing the myocardial oxygen demand below the level that would provoke an angina attack.</paragraph><paragraph>They are contraindicated in<space/><link><target>variant angina</target></link><space/>and can precipitate<space/><link><target>heart failure</target></link>. They are also contraindicated in severe asthmatics due to bronchoconstriction, and should be used cautiously in diabetics as they can cause hypoglycemia</paragraph><paragraph>Agents include either cardioselectives such as<space/><link><target>acebutolol</target></link><space/>or<space/><link><target>metoprolol</target></link>, or non-cardioselectives such as<space/><link><target>oxprenolol</target></link><space/>or<space/><link><target>sotalol</target></link>.</paragraph><heading level='3'>Calcium channel blockers</heading><paragraph><link><target>Calcium</target></link><space/><link><target>ion</target></link><space/>(Ca<xhtml:sup>++</xhtml:sup>) antagonists (<link><target>Calcium channel blocker</target><trail>s</trail></link>) are used in the treatment of chronic stable angina, and most effectively in the treatment of variant angina (directly preventing coronary artery vasospasm). They are not used in the treatment of unstable angina .<space/></paragraph><paragraph>In vitro, they dilate the coronary and peripheral arteries and have negative<space/><link><target>inotropic</target></link><space/>and<space/><link><target>chronotropic</target></link><space/>effects - decreasing<space/><link><target>afterload</target></link>, improving myocardial efficiency, reducing<space/><link><target>heart rate</target></link><space/>and improving coronary blood flow.<italics>In vivo</italics>, the vasodilation and<space/><link><target>hypotension</target></link><space/>trigger the<space/><link><target>baroreceptor</target></link><space/>reflex. Therefore the net effect is the interplay of direct and reflex actions.</paragraph><list type='bullet'><listitem>Class I agents have the most potent negative inotropic effect and may cause heart failure.</listitem><listitem>Class II agents do not depress conduction or contractility.</listitem><listitem>Class III agent has negligible inotropic effect and causes almost no reflex<space/><link><target>tachycardia</target></link>.</listitem></list><paragraph>Examples include Class I agents (<italics>e.g.</italics>,<space/><link><target>verapamil</target></link>), Class II agents (<italics>e.g.</italics>,<space/><link><target>amlodipine</target></link>,<space/><link><target>nifedipine</target></link>), or the Class III agent<space/><link><target>diltiazem</target></link>.</paragraph><paragraph><link><target>Nifedipine</target></link><space/>is more a potent vasodilator and more effective in angina. It is in the class of<space/><link><target>dihydropyridine</target><trail>s</trail></link><space/>and does not affect refrectory period on SA node conduction.</paragraph><heading level='2'>References</heading><paragraph><template><target>reflist</target></template></paragraph><paragraph><template><target>Major Drug Groups</target></template><template><target>Adrenergics</target></template><template><target>Vasodilators used in cardiac diseases</target></template><template><target>Nonsympatholytic vasodilatory antihypertensives</target></template></paragraph><paragraph><link><target>Category:Antianginals</target><part></part></link></paragraph></article>